Johnson & Johnson said on Friday it has discontinued a mid-stage study of its experimental drug to treat patients with moderate to severe atopic dermatitis, after it failed to meet efficacy goals in an interim analysis.
https://www.yahoo.com/news/articles/johnson-johnson-halts-mid-stage-131311676.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.